Clinical Trial Update: Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update investigating safety, tolerability, and maximum tolerated dose of SCO-101 in combination with gemcitabine and nab-paclitaxel for inopera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inoperable Pancreatic Cancer
• Localized Pancreatic Adenocarcinoma
• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• SCO-101

Snippet

Sponsor: Scandion Oncology A/S | Conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN